MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2023

Mar 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK: 0001157601
Period of Report: 2023-02-28

Reporting Person: Waltermire Robert E. (Senior VP, Chief Pharma Dev.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-28	Common Stock	M	5000	$87.92	Acquired	10667	Direct
2023-02-28	Common Stock	S	900	$271.03	Disposed	9767	Direct
2023-02-28	Common Stock	S	4100	$272.30	Disposed	5667	Direct
2023-03-01	Common Stock	M	5000	$87.92	Acquired	10667	Direct
2023-03-01	Common Stock	S	1928	$273.44	Disposed	8739	Direct
2023-03-01	Common Stock	S	1672	$274.57	Disposed	7067	Direct
2023-03-01	Common Stock	S	1300	$275.53	Disposed	5767	Direct
2023-03-01	Common Stock	S	100	$276.19	Disposed	5667	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-28	Stock Option (Right to Buy)	$87.92	M	5000	Disposed	2031-08-02	Common Stock (5000)	Direct
2023-03-01	Stock Option (Right to Buy)	$87.92	M	5000	Disposed	2031-08-02	Common Stock (5000)	Direct

Footnotes

F1: All shares issued pursuant to the exercise of the options reported herein represent 10,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.58 to $271.47, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.82 to $272.77, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.00 to $274.00, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.06 to $274.99, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.18 to $276.18, inclusive.